Drug intelligence / Profile preview

Alivet FA

Development stage
Unknown
Lead developer
Megat Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Alivet FA is a multi-symptom combination pharmaceutical product developed and marketed by Megat Pharmaceutical in Ecuador for the treatment of the common cold and flu. It is formulated as coated tablets containing four active ingredients: acetaminophen (650 mg), pseudoephedrine hydrochloride (30 mg), dextromethorphan hydrobromide (20 mg), and chlorpheniramine maleate (4 mg). Acetaminophen provides analgesic and antipyretic effects, pseudoephedrine acts as a nasal decongestant, dextromethorphan serves as an antitussive to suppress dry cough, and chlorpheniramine is an antihistamine that relieves allergic-like symptoms such as sneezing and watery eyes. The product is positioned within the primary care segment for the symptomatic relief of respiratory infections accompanied by congestion and non-productive cough.

Brand names
Alivet FA
02

Targets

SIGMAR1 (Sigma non-opioid intracellular receptor 1)ADRA1A (α1A)HRH1 (Histamine H1 Receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Alivet FA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alivet FA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call